Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BNTX
stocks logo

BNTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
823.11M
-30.83%
-0.060
-105.54%
219.20M
+19.91%
-2.030
+17.34%
268.65M
+3.01%
-2.188
+36.75%
Estimates Revision
The market is revising Upward the revenue expectations for BioNTech SE (BNTX) for FY2025, with the revenue forecasts being adjusted by 13.49% over the past three months. During the same period, the stock price has changed by -14.64%.
Revenue Estimates for FY2025
Revise Upward
up Image
+13.49%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-7.45%
In Past 3 Month
Stock Price
Go Down
down Image
-14.64%
In Past 3 Month
Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 140.25 USD with a low forecast of 107.00 USD and a high forecast of 181.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 140.25 USD with a low forecast of 107.00 USD and a high forecast of 181.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
3 Hold
0 Sell
Strong Buy
Current: 96.000
sliders
Low
107.00
Averages
140.25
High
181.00
Current: 96.000
sliders
Low
107.00
Averages
140.25
High
181.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$136 -> $140
2025-11-10
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$136 -> $140
2025-11-10
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on BioNTech to $140 from $136 and keeps a Buy rating on the shares. The firm updated the company's model post the Q3 report to reflect lower operating expenses.
UBS
Eliana Merle
Neutral
maintain
$115 -> $117
2025-11-06
Reason
UBS
Eliana Merle
Price Target
$115 -> $117
2025-11-06
maintain
Neutral
Reason
UBS analyst Eliana Merle raised the firm's price target on BioNTech to $117 from $115 and keeps a Neutral rating on the shares. The Pumitamig data update in first-line treatment for small cell lung cancer has de-risked the pipeline, the analyst tells investors in a research note.
BofA
Tazeen Ahmad
Buy
maintain
$130 -> $134
2025-11-04
Reason
BofA
Tazeen Ahmad
Price Target
$130 -> $134
2025-11-04
maintain
Buy
Reason
BofA analyst Tazeen Ahmad raised the firm's price target on BioNTech to $134 from $130 and keeps a Buy rating on the shares. Despite the COVID revenue beat, the firm continues to see risk for long-term adoption. However, it notes that the company is well-positioned to advance the oncology franchise, which BofA sees as "the key long-term driver."
Clear Street
Bill Maughan
Buy
downgrade
$185 -> $181
2025-11-03
Reason
Clear Street
Bill Maughan
Price Target
$185 -> $181
2025-11-03
downgrade
Buy
Reason
Clear Street analyst Bill Maughan lowered the firm's price target on BioNTech (BNTX) to $181 from $185 and keeps a Buy rating on the shares. The firm updated the company's model post the Q3 report. Today's selloff is related to the regulatory readthrough from an adverse FDA communication to uniQure (QURE), the analyst tells investors in a research note. Clear Street views BioNTech's updated guidance as a "healthy sign of a company improving its operating efficiency."
Morgan Stanley
Overweight
maintain
$131 -> $134
2025-11-03
Reason
Morgan Stanley
Price Target
$131 -> $134
2025-11-03
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on BioNTech to $134 from $131 and keeps an Overweight rating on the shares. Comirnaty Q3 revenues were ahead of consensus, and the company noted that the COVID-19 franchise is performing in-line with expectations, the analyst tells investors in a research note. The firm added BioNTech has seen and continues to expect stable share andd pricing.
BofA
Tazeen Ahmad
Buy
downgrade
$134 -> $130
2025-10-22
Reason
BofA
Tazeen Ahmad
Price Target
$134 -> $130
2025-10-22
downgrade
Buy
Reason
BofA analyst Tazeen Ahmad lowered the firm's price target on BioNTech to $130 from $134 and keeps a Buy rating on the shares. The firm adjusted targets among its small-to-mid cap biotech coverage as part of a Q3 earnings preview for the group.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Biontech SE (BNTX.O) is -17.63, compared to its 5-year average forward P/E of -5.00. For a more detailed relative valuation and DCF analysis to assess Biontech SE 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.00
Current PE
-17.63
Overvalued PE
4.99
Undervalued PE
-15.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
2.79
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
12.67
Undervalued EV/EBITDA
-7.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.95
Current PS
0.00
Overvalued PS
8.78
Undervalued PS
3.11
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BNTX News & Events

Events Timeline

(ET)
2025-12-03
09:10:00
BioNTech Completes CureVac Acquisition with 184,071,410 Shares Validly Tendered
select
2025-12-02 (ET)
2025-12-02
06:20:00
Kennedy Advisers Consider Major Revisions to Childhood Vaccination Schedule
select
link
2025-12-01 (ET)
2025-12-01
11:20:00
BofA Maintains $6 Price Target on Novavax Amid Negative Vaccine News
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
12-04SeekingAlpha
Ex-FDA Commissioners Criticize Proposal to Alter Vaccine Approval Criteria

  • Former FDA Commissioners' Opposition: A dozen former FDA commissioners have criticized a new plan by vaccine official Vinay Prasad to change vaccine approval standards, claiming it could undermine public trust and health safety.

  • Concerns Over Regulatory Changes: The proposed changes are seen as a significant shift that could hinder vaccine innovation and slow the introduction of improved vaccines, particularly in response to evolving viruses.

  • Impact on Vaccine Approval Process: The former commissioners argue that the new guidelines would impose a higher and more subjective approval standard, potentially creating barriers for new entrants in the vaccine market.

  • Delay in Vaccine Updates: Prasad's call for new studies on regularly updated vaccines, like flu and COVID, is viewed as a potential delay in delivering better-matched vaccines during outbreaks.

[object Object]
Preview
8.5
12-03Globenewswire
BioNTech Acquires 81.74% of CureVac Shares in Exchange Offer
  • Acquisition Progress: BioNTech successfully acquired 184,071,410 shares of CureVac, representing approximately 81.74% of its issued shares, satisfying the minimum condition for the exchange offer and marking a significant advancement in the acquisition process.
  • Subsequent Arrangements: The subsequent offering period has commenced and will expire on December 18, 2025, allowing CureVac shareholders who have not yet tendered their shares to do so, further facilitating the completion of the transaction.
  • Shareholder Impact: Non-tendering shareholders will receive BioNTech American Depositary Shares in the post-offer reorganization, which may be subject to a 15% Dutch dividend withholding tax, potentially affecting their investment returns.
  • Market Reaction: This acquisition is expected to further solidify BioNTech's market position in the biopharmaceutical sector, likely driving the development and market expansion of its innovative therapies.
[object Object]
Preview
8.5
12-03Newsfilter
BioNTech Acquires 81.74% of CureVac Shares in Exchange Offer
  • Acquisition Progress: BioNTech has successfully acquired 81.74% of CureVac's shares, satisfying the minimum condition for the exchange offer, which signifies further consolidation and expansion in the biopharmaceutical sector.
  • Subsequent Offer Period: The subsequent offering period has commenced and will expire on December 18, 2025, allowing CureVac shareholders who have not yet tendered their shares to do so, enhancing the transaction's flexibility and appeal.
  • Tax Implications: Non-tendering CureVac shareholders will face a 15% Dutch dividend withholding tax during the post-offer reorganization, which may impact their investment returns and requires careful consideration.
  • Market Reaction: This acquisition is expected to significantly enhance BioNTech's competitiveness in the global biopharmaceutical market, particularly in the field of cancer immunotherapy, likely driving its future R&D and market expansion efforts.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Biontech SE (BNTX) stock price today?

The current price of BNTX is 96 USD — it has decreased -0.75 % in the last trading day.

arrow icon

What is Biontech SE (BNTX)'s business?

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

arrow icon

What is the price predicton of BNTX Stock?

Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 140.25 USD with a low forecast of 107.00 USD and a high forecast of 181.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Biontech SE (BNTX)'s revenue for the last quarter?

Biontech SE revenue for the last quarter amounts to 1.52B USD, increased 22.02 % YoY.

arrow icon

What is Biontech SE (BNTX)'s earnings per share (EPS) for the last quarter?

Biontech SE. EPS for the last quarter amounts to -0.12 USD, decreased -114.81 % YoY.

arrow icon

What changes have occurred in the market's expectations for Biontech SE (BNTX)'s fundamentals?

The market is revising Upward the revenue expectations for BioNTech SE (BNTX) for FY2025, with the revenue forecasts being adjusted by 13.49% over the past three months. During the same period, the stock price has changed by -14.64%.
arrow icon

How many employees does Biontech SE (BNTX). have?

Biontech SE (BNTX) has 6772 emplpoyees as of December 05 2025.

arrow icon

What is Biontech SE (BNTX) market cap?

Today BNTX has the market capitalization of 23.08B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free